cancers-logo

Journal Browser

Journal Browser

Announcements

8 July 2025
MDPI’s Journal Cluster of Oncology


According to the World Health Organization, cancer is a leading cause of mortality and accounted for approximately 10 million deaths in 2020. Therefore, continued research regarding understanding, diagnosing, and treating cancer is a global priority. The ever-evolving field of oncology spans innovations and discoveries in tumor biology, immunotherapy, targeted treatments, early detection, and personalized medicine.

The mission of MDPI’s cluster of oncology-related journals is to publish high-impact research with potential to redefine cancer treatment and care. Addressing topics from solid tumors to hematologic malignancies, from rare cancers to novel therapeutics, these journals provide a dynamic platform for groundbreaking discoveries and clinical advancements that shape the future of oncology.

The four participating journals are as follows:

  • Cancers (ISSN: 2072-6694) focuses on publishing high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics. In particular, it showcases the most seminal studies in the rapidly growing areas of immunology, immunotherapy, and tumor microenvironment research. Cancers is led by its Editor-in-Chief, Prof. Dr. Samuel C. Mok;
  • Current Oncology (ISSN: 1718-7729) is dedicated to advancing cancer care and therapy via publishing clinically relevant research with direct applications to oncology practice. Since its establishment in 1994, the journal has played an important role in disseminating new knowledge across the entire cancer care continuum, spanning the prevention, early detection, and diagnosis of cancer; treatment, including systemic therapy, radiation therapy, and surgery; supportive care; and survivorship care. Additionally, it highlights the critical role of biomarkers and biomarker-driven research in guiding personalized oncology. Affiliated with several key cancer societies, Current Oncology provides a global platform to share scientific progress in oncology. The journal is led by its Editor-in-Chief, Prof. Dr. Shahid Ahmed;
  • Onco (ISSN: 2673-7523) functions as a scientific forum integrating novel preclinical, translational, and clinical cancer research and is focused on (but not limited to) the following topics: cancer cell signaling; cancer genetics and molecular targets; cancer epigenetics and heterogeneity; carcinogenesis and cancer evolution; microbiomes and cancer; cancer metabolomics; cancer biomarkers; cancer dormancy; novel targeted and immune cancer therapies; randomized clinical trials; oncotargets; cancer therapies; and clinical reports proposing novel therapeutic regimens. Onco is led by its Editor-in-Chief, Dr. Constantin N. Baxevanis;
  • Targets (ISSN: 2813-3137) is centered on, but not limited to, discovering novel molecules which act as diagnostic biomarkers and therapeutic targets, establishing new bionic recognition systems for biosensing and bioimaging, developing novel approaches for biomarker detection, related applications of biological interaction monitoring and targeted therapy, designing new signal amplification strategies for biosensing and cellular or in vivo imaging, utilizing molecular recognition for single-molecule or single-cell analysis, elucidating new pathways or mechanisms in disease development and progression, and synthesizing smart nanomaterials for activatable imaging and responsive drug release. Targets is led by its Editor-in-Chief, Prof. Dr. Huangxian Ju.

 

Launch Year

Impact Factor (2024)

CiteScore (2024)

Time to First Decision (Median)

APC (CHF)

2009

4.4

8.8

17.4 days

2900

1994

3.4

4.9

19.8 days

2200

2021

/

/

27.8 days

1000

2023

/

/

28.4 days

1000

MDPI’s mission and values:

As a pioneer in academic open access publishing, MDPI has been serving the scientific community since 1996. Our aim is to foster scientific exchange in all forms and across all disciplines. MDPI's guidelines for disseminating open science are based on the following values and guiding principles:

  • Open Access—All our content is published in open access format and distributed under a Creative Commons License, providing free access to the latest research and allowing articles to be freely shared and content to be re-used with proper attribution;
  • Timeliness and Efficiency—We rapidly publish novel research through a thorough editorial process, ensuring that a first decision is provided to authors in under 32 days and that papers are published within 7–10 days upon acceptance;
  • Simplicity—We offer user-friendly tools and services on our integrated system to enhance the efficiency of our editorial process;
  • High-Quality Service—We support scholars and their work by providing a range of options, such as publication in journals at mdpi.com, early publication at preprints.org, and the publication of conferences at sciforum.net, to positively impact research;
  • Flexibility—We adapt and develop new tools and services to meet the changing needs of the research community, driven by feedback from authors, editors, and readers;
  • Rooted in Sustainability—We ensure the long-term preservation of published papers and support the future of science through partnerships, sponsorships, and awards.

By adhering to these values and principles, MDPI remains committed to advancing scientific knowledge and promoting open-science practices.

Selected Topics:

Selected Articles:

Cancers
Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment
Cancers 2024, 16(12), 2171; https://doi.org/10.3390/cancers16122171

Current Oncology
Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Curr. Oncol. 2023, 30(2), 2322-2347; https://doi.org/10.3390/curroncol30020179

Onco
Significance of PET/CT Imaging in Myeloma Assessment: Exploring Novel Applications beyond Osteolytic Lesion Detection and Treatment Response
Onco 2024, 4(1), 15-36; https://doi.org/10.3390/onco4010002

Targets
Potential of MMP-2 and MMP-9 Gelatinase Blockade as a Therapeutic Strategy in Fibrosarcoma Treatment: A Decadal Review
Targets 2024, 2(2), 104-125; https://doi.org/10.3390/targets2020007

4 July 2025
MDPI’s Newly Launched Journals in June 2025

Six new journals covering a range of subjects launched their inaugural issues in June 2025. We are excited to be able to share with you the newest research rooted in the value of open access. We are pleased to present the latest research and to make it accessible to all.

We extend our sincere thanks to all the Editorial Board Members for their commitment and expertise. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

Journal Founding Editor-in-Chief Journal Topics (Selected)
Prof. Dr. Chang-Pu Sun,
China Academy of Engineering Physics, Beijing, China; Computational Science Research Center, China
Editorial | View inaugural issue
quantum information and phenomena; condensed matter physics and statistical physics; atomic, molecular, and optical physics; computational physics and mathematical methods
View journal scope | Submit an article
Prof. Dr. Hualiang Lin,
Sun Yat-sen University, China;
Prof. Dr. Jose L. Domingo,
Universitat Rovira i Virgili, Spain
Editorial | View inaugural issue
green and organic food; green infrastructures; green exercise; environmental impact of the healthcare sector; effects of climate change on human health |
View journal scope | Submit an article
Prof. Dr. Francesco Veglio,
University of L’Aquila, Italy
Editorial | View inaugural issue
ultra-pure substances; water purification; air purification; gas purification; inorganic chemical purification; purification technologies
View journal scope | Submit an article
Prof. Dr. Junxing Zheng,
Huazhong University of Science and Technology, China
Editorial | View inaugural issue
computer-aided design and engineering; artificial intelligence and machine learning; building information modeling (BIM) and digital twins; robotics and automation in construction; smart sensors and Internet of Things (IoT); intelligent control systems and facilities management
View journal scope | Submit an article
Prof. Dr. Assunta Di Vaio,
University of Naples Parthenope, Italy
Editorial | View inaugural issue
sustainability, managerial, and biodiversity accounting; carbon management accounting; corporate social responsibility; artificial intelligence and disclosure
View journal scope | Submit an article
Prof. Dr. Changjun Liu,
Sichuan University, China
Editorial | View inaugural issue
bioeffects of electromagnetic waves; electromagnetic science and engineering; microwave, millimeter-wave, and terahertz technologies; metamaterials and metasurfaces; communication, sensing, and networks; energy, power, and sustainable applications; quantum and emerging technologies; artificial intelligence and advanced fabrication
View journal scope | Submit an article
We wish to thank everyone who has supported the development of open access publishing. If you are interested in launching a new open access journal with us, you are welcome to send an application here.

2 July 2025
MDPI INSIGHTS: The CEO's Letter #24 - 2024 Impact Factor & CiteScore, MDPI Summits France & USA, Tu Youyou Award

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI’s 2024 Impact Factor Highlights

For those of our readers who are new to academic publishing, you may have heard some news in June around the Impact Factor release. Every year, typically in June, Clarivate releases its annual Journal Citation Reports (JCR), which include Journal Impact Factors (JIF). This metric is widely used in academic publishing to reflect the average number of citations received by recent articles in each journal.

While Impact Factor is just one of many indicators of journal influence, it remains a major milestone for authors, editors, and publishers. It’s used to assess journal visibility, researcher recognition, and scholarly reach. Throughout our international meetings and events, it’s clear that the Impact Factor is something many of our authors and editorial board members care about, as it can influence where they choose to submit an article and the funding they receive for their research.

“These results reflect the trust that the scholarly community places in MDPI”

MDPI’s 2024 Impact Factor Highlights

  • 298 MDPI journals received a Journal Impact Factor.
  • 60 journals earned their first-ever Impact Factor
    • To put this in perspective: MDPI’s 60 new journal acceptances into the Web of Science was the second highest number of any publisher in 2024, behind Elsevier and ahead of Springer Nature. Our 87% acceptance rate for journals submitted to Web of Science shows the strength of our editorial process and our proven ability to develop journals aligned with Clarivate’s 24 evaluation criteria.
    • Notably, Textiles, Mathematics, International Journal of Neonatal Screening, Smart Cities, Systems, and Pharmaceutics ranked in the top 10% in their respective categories, highlighting their growing influence and prestige within their academic fields. This shows that high-quality indexing goes beyond visibility; it upholds credibility and trust.
  • 193 MDPI journals are now ranked in the top 50% (Q1/Q2) of their subject categories.
    • What does this mean, and why is it important? Journals are ranked by quartiles within their field, based on their Impact Factor. Q1 represents the top 25% of journals in their category, Q2 the next 25%, and so on. Being in Q1 or Q2 shows that a journal is performing well relative to other journals in its category. Authors and institutions often look at quartile rankings when choosing where to publish – it’s an important indicator of visibility and recognition, within its respective category.
  • 116 of our previously ranked journals increased their Impact Factor.
  • 14 MDPI journals achieved an Impact Factor of 5.0 or higher, suggesting a high degree of influence and visibility.

These results reflect our staff's hard work: from our editorial and production teams to our indexing, communications, and data teams, and beyond. This also reflects the trust that the scholarly community places in MDPI, reinforcing the message that when researchers publish with MDPI, they publish with impact.

Open Access with Impact

As the leading fully open access publisher, our journals have received a total of 18.4 million citations in the Web of Science by the end of 2024, reflecting the growing reach and engagement of research published with MDPI. We are committed to making scientific research freely accessible to everyone, everywhere. With the support of more than 4.2 million contributing authors, we’re proud to support the global shift toward open access.

Further Reading

If you’d like to better understand how journals get indexed and why Impact Factors matter, please read this recent interview with Dr. Constanze Schelhorn (Head of Indexing). It gives you a behind-the-scenes look at the role our indexing team plays in supporting journal indexing and visibility.

You can also read our official news announcement shared last week: MDPI Journals in the 2024 Journal Citation Reports.

Thank you to everyone, from our authors and reviewers to our editors and internal teams, who contributed to the progress of our journal indexing in 2024. We’re continuing to build journals that are recognized and trusted across disciplines.

Impactful Research

MDPI Journals See Continued Growth in 2024 CiteScore Results

Continuing our indexing updates, I’m pleased to share that MDPI has achieved strong results in the latest CiteScore metrics, released on 5 June by Scopus. These results reflect the collective efforts of our editors, reviewers, authors, and internal teams, with their dedication to quality and visibility in scientific publishing. You can read the full announcement here.

2024 Highlights:

  • 322 MDPI journals received a CiteScore (up from 274 last year).
  • 283 journals (88%) are ranked in Q1 or Q2 of their subject categories.
  • 237 journals (85%) saw an increase in their CiteScore compared to last year.
  • 48 journals received a CiteScore for the first time.
  • 39 journals are now placed in the top 10% of their subject areas.

“This growth highlights our commitment to supporting open, trusted science”

What is CiteScore and how is it measured?

CiteScore metrics are developed by Elsevier as an alternative to the Impact Factor. They measure the citation impact of journals and can be accessed freely on Scopus. The metric represents the yearly average number of citations to recent articles published in a journal. If you’re interested in learning more about citation metrics and how we use them, check out this blog post.

Why is this important?

These results show the growing recognition for, and impact of, MDPI journals across disciplines. CiteScore rankings help researchers, institutions, and funders assess where high-quality work is being published. This growth improves our journals’ positioning in the publishing landscape and highlights our commitment to supporting open, trusted science.

Inside MDPI

Highlights from the MDPI USA Summit in Boston (5–6 June)

With several Summits already behind us, I think this is a good time to reflect on the purpose of these Summits.

Why do we organize MDPI Summits?

These one-and-a-half-day, invite-only gatherings are designed to improve our relationships with Chief Editors who lead our journals and are respected voices in their fields. The Summits aim to:

  1. Share MDPI’s values, achievements, editorial practices, and local market collaborations.
  2. Collect feedback on MDPI operations and journal practices.
  3. Empower Chief Editors to confidently represent MDPI beyond the Summit.

While Chief Editors know their journals well, these events help them better understand MDPI. We want them to be ambassadors for our brand. The aim is for them to walk away informed, engaged, and equipped to share positively about MDPI.

About the Boston Summit

Held on 5–6 June, our first USA Summit gathered over 25 Chief Editors to learn more about MDPI’s activities and collaborations in the USA. The program included presentations, Q&A, and a panel discussion.

Agenda Highlights:

Moderated by Summer Huggard (Operations Manager [Toronto], MDPI), the program featured:

  • MDPI Overview and USA Collaboration – Stefan Tochev (CEO, MDPI)
  • AI in Publishing and MDPI's Actions – Feichi Lu (Junior Data Scientist, MDPI)
  • MDPI Editorial Process and Research Integrity – Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI)
  • Panel Discussion – Stefan, Feichi, Giulia, Claudia
  • Society Partnerships – Dr. Clàudia Aunós (Society Partnerships Senior Manager, MDPI)
  • Voice of the Customer and Closing Remarks – Stefan Tochev (CEO, MDPI)

MDPI & the USA: Facts and Figures

  • With over 216,000 publications, the USA is MDPI’s second-largest contributor after China.
  • In 2024, the USA ranked 2nd in total submissions and 2nd in total MDPI publications, with more than 28,200 publications.
  • As of 2020, the cumulative number of authors from the USA until April 2025 was 352,099.
  • As at April 2025, there are more than 12,035 active Editorial Board Members (EBMs) from the USA, with 55% having an H-index over 26.
  • Among them, 96 serve as Editors-in-Chief (EiC) and 218 as section-Editors-in-Chief (SEiC)
  • MDPI has more than 920 Institutional Open Access Program agreements worldwide, with over 130 from the USA.

A special thanks to our Toronto team, and everyone who worked behind the scenes to make this event run smoothly.

Coming Together for Science

Highlights from the MDPI France Summit in Paris (12–13 June)

We completed our first MDPI France Summit in Paris last week, and it was a special event. Attendees were engaged from beginning to end, remaining after hours to network and collaborate.

Why a France Summit?

We chose to host a France Summit in view of the recent challenges MDPI has faced with the National Centre for Scientific Research (CNRS). What we took away from the event is that our authors and editors very much appreciate and enjoy working with us, but we need to address the concerns raised by CNRS, around Article Processing Charges (APCs) and the funding of gold open access publications.

“Our authors and editors very much enjoy working with us”

Some of the claims made in the June 2023 interview with Alain Schuhl, the Deputy CEO for Science at the CNRS, are simply not factual. For example, they state that MDPI’s “average APC charges per article are now around the same as Springer Nature’s.” Here is the relevant passage, reproduced verbatim:

This is not accurate.

A recent preprint analysing APC data from Elsevier, Springer Nature, Wiley, PLOS, MDPI, and Frontiers (2019–2023) shows that MDPI’s average APCs remain significantly lower than those of Springer Nature and several other major publishers.

The MDPI Summits are part of our outreach and communication efforts to address misconceptions and clarify MDPI’s position as one of the most accessible and affordable major gold open access publishers in the world.

Summit Overview

Held on 12–13 June, the France Summit gathered over 20 Chief Editors to learn more about MDPI’s activities and collaborations in France. Many of these editors are influential in their institutions and professional societies. Several also have connections to CNRS, which makes this an important opportunity to clarify how we operate and build trust through open and transparent communication and hopefully turn our editors into informed advocates of MDPI.

Summit Feedback

The feedback has been very positive, with most attendees completing the post-event survey and all rating the experience as Excellent or Good. A few highlights:

  • “The whole thing was highly professional and, above all, provided quantified details that will allow us to better answer questions surrounding MDPI.”
  • “The summit was an opportunity to meet personally various people directly engaged in the organization and policies of MDPI, which made it possible to clarify some important points concerning publishing with MDPI.”
  • “Very well organized! A great opportunity to see all French MDPI partners and editors.”

Program Highlights:

Moderated by Miruna Adelina Nicolcioiu (Senior Conference Producer), the program featured:

  • MDPI Overview and France Collaboration – Stefan Tochev (CEO)
  • MDPI Editorial Process and Peer-Review Quality – Dr. Marta Colomer (Public Affairs Specialist)
  • Institutional Partnerships and Open Access Funding Models – Becky Castellon (Institutional Partnerships Manager)
  • AI in Publishing and MDPI's Actions – Daniele Raimondi (Data Scientist)
  • Publication Ethics: Global Trends – Diana Cristina Apodaritei (Research Integrity Specialist)
  • Closing Remarks – Stefan Tochev
  • Panel Discussion – Diana, Becky, Prof. Dr. Patrick Da Cost, and Stefan

MDPI & France: Facts and Figures

  • With over 51,000 publications, France is MDPI's tenth-largest contributor, and fifth largest among EU countries after Italy, Spain, Germany, and Poland.
  • As of 2020, the cumulative number of authors from France until April 2025 was 87,592.
  • As at April 2025, there are more than 2,800 active Editorial Board Members (EBMs) from France, with 59% having an H-index over 26.
  • Among them, 22 serve as Editors-in-Chief (EiC) and 61 as section-Editors-in-Chief (SEiC)
  • In 2024, IJMS, JCM, and Molecules were the top three MDPI journals in terms of submissions from French-affiliated authors.

Special thanks to our colleagues from Romanian offices for organizing this successful event.

Closing Thoughts

Richard DiMarchi and Rolf Müller Share the 2024 Tu Youyou Award

As we wrap up this month’s newsletter, I’d like to take a moment to recognize the winners of the 2024 Tu Youyou Award, presented by our journal Molecules. I am pleased to share that the 2024 Tu Youyou Award has been conferred upon Richard DiMarchi and Rolf Müller, in recognition of their significant contributions to natural products chemistry and medicinal chemistry.

I invite you to read the editorial co-authored by the Tu Youyou Award Committee, which highlights the significance of the award and the remarkable impact of the recipients’ research.

A sincere thank-you to the 2024 Award Committee for their dedication and selection process, and congratulations once again to this year’s honourees. Your work exemplifies the kind of research MDPI is proud to support and amplify.

About the Tu Youyou Award
The 2024 Tu Youyou Award includes a total monetary prize of 100,000 Swiss Francs and a medal for each recipient. Established in 2016 to honour the pioneering spirit of Nobel laureate Tu Youyou, the Tu Youyou Award is an international award recognizing exceptional scholars dedicated to the fields of natural products chemistry and medicinal chemistry.

For further information about the award and the winners, please visit the Tu Youyou Award website.

Stefan Tochev
Chief Executive Officer
MDPI AG

24 June 2025
Meet Us at the 10th World Congress of the International Academy of Oral Oncology, 16–19 July 2025, Liverpool, UK


MDPI will be attending the 10th World Congress of the International Academy of Oral Oncology, which will be held from 16 to 19 July 2025 at the Arena and Conference (ACC) Liverpool in Liverpool, UK.

The International Academy of Oral Oncology (IAOO) is a multi-disciplinary community of clinicians and scientists working on issues relating to the etiopathogenesis, epidemiology, prevention and management or oral and perioral tumours of oral disease in patients with malignancies. The IAOO exists to bring together clinicians and scientists working in the field of oral oncology, so that advances in medical science can be achieved and quickly translated into benefits for patients.

The World Congress of the Academy is an opportunity for the IAOO community to meet and exchange ideas and innovations in the field of oral oncology. The Congress is the only global gathering of head and neck surgeons, radiation and medical oncologists, maxillo-facial surgeons, otorhinolaryngologists and all other allied specialists in oral cancer care.

The following open access journals will be represented at the conference:

If you are planning to attend, please do not hesitate to visit our booth. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit the following website: https://eu.eventscloud.com/website/14087/home/.

12 June 2025
International Albinism Awareness Day—“Demanding Our Rights: Protect Our Skin, Preserve Our Lives”, 13 June 2025


International Albinism Awareness Day 2025 underscores the urgent need for increased awareness, preventive care, and accessible healthcare for people with albinism. This year’s theme highlights the life-threatening impact of skin cancer among individuals with albinism and reinforces the importance of sun protection, early detection, and timely treatment.

Albinism is a rare, inherited genetic condition that affects the body’s ability to produce melanin, the pigment responsible for the color of our skin, hair, and eyes. People with albinism typically have very light skin and hair, alongside various vision impairments. While it is not contagious and does not affect intelligence, albinism is often misunderstood. This leads to stigmatization, discrimination, and even human rights violations in some regions where harmful myths persist.

Because they have little to no melanin, individuals with albinism are especially vulnerable to sun damage and face a significantly increased risk of developing skin cancer. Addressing this requires more than just clinical intervention—it calls for integrated healthcare policies and inclusive social systems that acknowledge both the medical and socio-political dimensions of the condition.

In recognition of this global observance, we invite you to explore a curated collection of articles and Special Issues from selected MDPI journals, including Biomedicines, Cancers, Children, Diagnostics, Genes, International Journal of Molecular Sciences, Journal of Clinical Medicine and Molecules. These open-access resources provide critical insights into the diagnosis, management, and complications of albinism, and promote cross-disciplinary collaboration between researchers, clinicians, and advocacy groups.

Together, through science, education, and empathy, we can foster a more inclusive world where people with albinism live free from discrimination and with access to the care they deserve.

Can a Portable Flash Visual Evoked Potential (VEP) Device Identify Chiasmal Decussation Anomalies in Albinism?
by Eloise Keeling, Perry Carter, Abdi Malik Musa, Fatima Shawkat, Helena Lee and Jay E. Self
Diagnostics 2025, 15(11), 1395; https://doi.org/10.3390/diagnostics15111395

Common Variants in the TYR Gene with Unclear Pathogenicity as the Cause of Oculocutaneous Albinism in a Cohort of Russian Patients
by Olga Shchagina, Anna Stepanova, Polina Mishakova, Vitaliy Kadyshev, Nina Demina, Ludmila Bessonova, Sofya Ionova, Daria Guseva, Andrey Marakhonov, Rena Zinchenko et al.
Biomedicines 2024, 12(10), 2234; https://doi.org/10.3390/biomedicines12102234

Functional Characterization of Splice Variants in the Diagnosis of Albinism
by Modibo Diallo, Cécile Courdier, Elina Mercier, Angèle Sequeira, Alicia Defay-Stinat, Claudio Plaisant, Shahram Mesdaghi, Daniel Rigden, Sophie Javerzat, Eulalie Lasseaux et al.
Int. J. Mol. Sci. 2024, 25(16), 8657; https://doi.org/10.3390/ijms25168657

Genetic Linkage between CAPN5 and TYR Variants in the Context of Albinism and Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Absence: A Case Report
by Mirjana Bjeloš, Ana Ćurić, Mladen Bušić, Benedict Rak and Biljana Kuzmanović Elabjer
Int. J. Mol. Sci. 2024, 25(12), 6442; https://doi.org/10.3390/ijms25126442

Missing Heritability in Albinism: Deep Characterization of a Hungarian Albinism Cohort Raises the Possibility of the Digenic Genetic Background of the Disease
by Nikoletta Nagy, Margit Pal, Jozsef Kun, Bence Galik, Peter Urban, Marta Medvecz, Beata Fabos, Alexandra Neller, Aliasgari Abdolreza, Judit Danis, Viktoria Szabo, Zhuo Yang, Stefanie Fenske, Martin Biel, Attila Gyenesei, Eva Adam and Marta Szell
Int. J. Mol. Sci. 2024, 25(2), 1271; https://doi.org/10.3390/ijms25021271

Does Foveal Hypoplasia Affect Emmetropization in Patients with Albinism?
by Line Kessel, Christine Dahlgren Bohnsack Kjølholm and Joaquim Torner Jordana
Children 2023, 10(12), 1910; https://doi.org/10.3390/children10121910

Vision-Related Quality of Life in Danish Patients with Albinism and the Impact of an Updated Optical Rehabilitation
by Kristian Lisbjerg, Joaquim Torner Jordana, Vibeke N. Brandt, Christine Kjølholm and Line Kessel
J. Clin. Med. 2023, 12(17), 5451; https://doi.org/10.3390/jcm12175451

Skin Pigmentation Types, Causes and Treatment—A Review
by Amin Mahmood Thawabteh, Alaa Jibreen, Donia Karaman, Alà Thawabteh and Rafik Karaman
Molecules 2023, 28(12), 4839; https://doi.org/10.3390/molecules28124839

Report of Hermansky–Pudlak Syndrome in Two Families with Novel Variants in HPS3 and HPS4 Genes
by Sadeeda Qaiser Zaman, Muhammad Anas, Gauhar Rehman, Qadeem Khan, Aiman Iftikhar, Mashal Ahmad, Muhammad Owais, Ilyas Ahmad, Osama Yousef Muthaffar, Angham Abdulrhman Abdulkareem et al.
Genes 2023, 14(1), 145; https://doi.org/10.3390/genes14010145

Diagnostic Yield of Genetic Testing for Ocular and Oculocutaneous Albinism in a Diverse United States Pediatric Population
by Kyle S. Chan, Brenda L. Bohnsack, Alexander Ing, Andy Drackley, Valerie Castelluccio, Kevin X. Zhang, Hanta Ralay-Ranaivo and Jennifer L. Rossen
Genes 2023, 14(1), 135; https://doi.org/10.3390/genes14010135

More than Skin Deep—Latest Advances in Congenital and Autoimmune Pigmentation Disorders
Guest Editor: Prof. Dr. Reinhart M. Speeckaert
Submission deadline: 25 August 2025
Melanin Pigmentation: Physiology and Pathology
Guest Editors: Prof. Dr. Shosuke Ito and Prof. Dr. Manickam Sugumaran
Submission deadline: 20 October 2025

11 June 2025
Cancers | National Cancer Survivor Month


June is Cancer Survivor Month, which is a month-long observance that celebrates the strength, resilience, and triumph of those who have battled cancer. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings in fields concerning cancer survivors, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information regarding this field.

The list of the relevant papers can be found below:

“Improving Quality of Life and Psychosocial Health for Penile Cancer Survivors: A Narrative Review”
by Von Marie Torres Irizarry, Irasema Concepcion Paster, Vanessa Ogbuji, D’Andre Marquez Gomez, Kyle Mccormick and Juan Chipollini
Cancers 2024, 16(7),1309; https://doi.org/10.3390/cancers16071309
Available online: https://www.mdpi.com/2072-6694/16/7/1309

“Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model”
by Kimberley T. Lee, Hailey W. Bulls, Aasha I. Hoogland, Brian W. James, Claudia B. Colon-Echevarria and Heather S. L. Jim
Cancers 2024, 16(14), 2571; https://doi.org/10.3390/cancers16142571
Available online: https://www.mdpi.com/2072-6694/16/14/2571

“Reviewing the Landscape of Cancer Survivorship: Insights from Dr. Lidia Schapira’s Programs and Beyond”
by Viviana Cortiana, Rabab Hunaid Abbas, Soumiya Nadar, Diksha Mahendru, Jade Gambill, Gayathri Pramil Menon, Chandler H. Park and Yan Leyfman
Cancers 2024, 16(6), 1216; https://doi.org/10.3390/cancers16061216
Available online: https://www.mdpi.com/2072-6694/16/6/1216

“Impact of Real-World Outpatient Cancer Rehabilitation Services on Health-Related Quality of Life of Cancer Survivors across 12 Diagnosis Types in the United States”
by Mackenzi Pergolotti, Kelley C. Wood, Tiffany D. Kendig and Stacye Mayo
Cancers 2024, 16(10), 1927; https://doi.org/10.3390/cancers16101927  
Available online: https://www.mdpi.com/2072-6694/16/10/1927  

“Pain in Long-Term Cancer Survivors: Prevalence and Impact in a Cohort Composed Mostly of Breast Cancer Survivors”
by Concepción Pérez, Dolores Ochoa, Noelia Sánchez, Ana Isabel Ballesteros, Sheila Santidrián, Isabel López, Rebeca Mondéjar, Thiago Carnaval, Jesús Villoria and Ramón Colomer
Cancers 2024, 16(8), 1581; https://doi.org/10.3390/cancers16081581
Available online: https://www.mdpi.com/2072-6694/16/8/1581

“Household Income Is Associated with Chronic Pain and High-Impact Chronic Pain among Cancer Survivors: A Cross-Sectional Study Using NHIS Data”
by Nimish Valvi, Javier A. Tamargo, Dejana Braithwaite, Roger B. Fillingim and Shama D. Karanth
Cancers 2024, 16(16), 2847; https://doi.org/10.3390/cancers16162847
Available online: https://www.mdpi.com/2072-6694/16/16/2847

“The Cancer Patient Empowerment Program: A Comprehensive Approach to Reducing Psychological Distress in Cancer Survivors, with Insights from a Mixed-Model Analysis, Including Implications for Breast Cancer Patients”
by Gabriela Ilie, Gregory Knapp, Ashley Davidson, Stephanie Snow, Hannah M. Dahn, Cody MacDonald, Markos Tsirigotis and Robert David Harold Rutledge
Cancers 2024, 16(19), 3373; https://doi.org/10.3390/cancers16193373
Available online: https://www.mdpi.com/2072-6694/16/19/3373

“Role of Nutraceuticals in Counteracting Inflammation in In Vitro Macrophages Obtained from Childhood Cancer Survivors”
by Alessandra Di Paola, Maria Maddalena Marrapodi, Elvira Pota, Rosa Colucci Cante, Deeksha Rana, Giulia Giliberti, Giuseppe Di Feo, Shakeel Ahmed, Domenico Roberti, Roberto Nigro et al.
Cancers 2024, 16(4), 714; https://doi.org/10.3390/cancers16040714
Available online: https://www.mdpi.com/2072-6694/16/4/714

“Features of Studies on Transition Interventions for Childhood Cancer Survivors: A Scoping Review”
by Jun Ma, Xueling Xiao, Siqi Zhou, Can Gu, Fei Liu and Honghong Wang
Cancers 2024, 16(2), 272; https://doi.org/10.3390/cancers16020272
Available online: https://www.mdpi.com/2072-6694/16/2/272

“Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study”
by Nathalie Vanlaer, Iris Dirven, Bart Neyns and Anne Rogiers
Cancers 2024, 16(9), 1638; https://doi.org/10.3390/cancers16091638
Available online: https://www.mdpi.com/2072-6694/16/9/1638

“Impact of Pre-Diagnostic Risk Factors on Short- and Long-Term Ovarian Cancer Survival Trajectories: A Longitudinal Observational Study”
by Shana J. Kim, Shelley S. Tworoger, Barry P. Rosen, John R. McLaughlin, Harvey A. Risch, Steven A. Narod and Joanne Kotsopoulos
Cancers 2024, 16(5), 972; https://doi.org/10.3390/cancers16050972
Available online: https://www.mdpi.com/2072-6694/16/5/972

“The Role of Amide Proton Transfer (APT)-Weighted Imaging in Glioma: Assessment of Tumor Grading, Molecular Profile and Survival in Different Tumor Components”
by Gonçalo Borges de Almeida, Riccardo Pascuzzo, Francesca Mambrin, Domenico Aquino, Mattia Verri, Marco Moscatelli, Massimiliano Del Bene, Francesco DiMeco, Antonio Silvani, Bianca Pollo et al.
Cancers 2024, 16(17), 3014; https://doi.org/10.3390/cancers16173014  
Available online: https://www.mdpi.com/2072-6694/16/17/3014

“Characterization of Patient Activation among Childhood Cancer Survivors in the St. Jude Lifetime Cohort Study (SJLIFE)”
by Megan E. Ware, Angelica De La Cruz, Qian Dong, Kyla Shelton, Tara M. Brinkman, I-Chan Huang, Rachel Webster, Brian Potter, Kevin Krull, Sedigheh Mirzaei et al.
Cancers 2024, 16(18), 3220; https://doi.org/10.3390/cancers16183220
Available online: https://www.mdpi.com/2072-6694/16/18/3220

“Menopausal Hormone Therapy in Breast Cancer Survivors”
by Rose Culhane, Alexandra M. Zaborowski and Arnold D. K. Hill
Cancers 2024, 16(19), 3267; https://doi.org/10.3390/cancers16193267
Available online: https://www.mdpi.com/2072-6694/16/19/3267

You are welcome to submit relevant papers to Cancers.

Cancers Editorial Office

10 June 2025
Cancers Receives an Increased CiteScore of 8.8


We are pleased to share that Cancers (ISSN: 2072-6694) has received an increased CiteScore of 8.8 in June 2025. The CiteScore ranks the journal 68 out of 415 titles (Q1) in the “Oncology” category, an impressive achievement for a journal running in Volume 17.

You can find more statistics on our website.

The current CiteScores measure the average number of citations within a journal over a four-year window (2021–2024). The Scopus database provides a comprehensive suite of metrics that support informed publishing strategies, research evaluation and enable benchmarking of journal performance.

This achievement reflects the collective efforts of our authors, reviewers, and editors. Together we will continue to track the progress of Cancers and its growing impact in oncology.

10 June 2025
Welcoming New Editorial Board Members of Cancers Joined in June 2025

We are pleased to announce that six new scholars have been appointed as Editorial Board Members (EBMs) of Cancers (ISSN: 2072-6694), joining in June 2025. We wish our new members success in both their research and their efforts to develop the journal.

Name: Prof. Dr. Aria Baniahmad
Affiliation: Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, Jena 07747, Germany
Interests: Androgen regulation of prostate cancer; Androgen receptor biology; Cellular senescence in cancer

Name: Prof. Dr. Daniele Generali
Affiliation: Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy
Interests: breast cancer; molecular oncology

Name: Dr. Jesus Garcia-Foncillas
Affiliation: Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain
Interests: cancer biomarkers; oncology; precision medicine

Name: Prof. Dr. Marco Demaria
Affiliation: European Institute for the Biology of Aging (ERIBA), University Medical Center Groningen, University of Groningen, 9713 AV Groningen, the Netherlands
Interests: cellular senescence; molecular cancer biology; tumor microenvironment; responses to cancer treatment; aging; cell cycle arrest

Name: Prof. Dr. Michaela Luconi
Affiliation: Department of Experimental and Clinical Biomedical Sciences, Endocrinology Unit, University of Florence, I‐50139 Florence, Italy
Interests: adrenal tumors; molecular and cell biology of endocrine tumors and metabolic pathologies

Name: Dr. Stacey Edwards
Affiliation: Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia
Interests: molecular biology; gene regulation; noncoding RNAs; chromatin conformation; post-GWAS functional studies; breast cancer; ovarian cancer

Further details about the Editorial Board of Cancers can be found by clicking the following link: https://www.mdpi.com/journal/cancers/editors.

Cancers is recruiting scholars from around the world to join our Editorial Board.

To apply for membership, recommend potential candidates, or request further information, please contact the Cancers Editorial Office and provide the following files:

  • A full academic CV;
  • A short cover letter detailing your interest in the position.

3 June 2025
Cancers | Feature Papers from the First Half of 2024 in the “Pediatric Oncology” Section


As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the “Pediatric Oncology” Section, which are listed below.

1. “Therapeutic Parent–Child Communication and Health Outcomes in the Childhood Cancer Context: A Scoping Review”
by Heeyeon Son and Nani Kim
Cancers 2024, 16(11), 2152; https://doi.org/10.3390/cancers16112152
Available online: https://www.mdpi.com/2072-6694/16/11/2152

2. “Telomere Length in Adolescent and Young Adult Survivors of Childhood Cancer”
by Meerim Park, Dong-Eun Lee, Yuna Hong, Jin Kyung Suh, Jun Ah Lee, Myungshin Kim and Hyeon Jin Park
Cancers 2024, 16(13), 2344; https://doi.org/10.3390/cancers16132344
Available online: https://www.mdpi.com/2072-6694/16/13/2344

3. “Non-Syndromic and Syndromic Defects in Children with Extracranial Germ Cell Tumors: Data of 2610 Children Registered with the German MAKEI 96/MAHO 98 Registry Compared to the General Population”
by Judit H. Schultewolter, Anke Rissmann, Dietrich von Schweinitz, Michael Frühwald, Claudia Blattmann, Lars Fischer, Björn Sönke Lange, Rüdiger Wessalowski, Birgit Fröhlich, Wolfgang Behnisch et al.
Cancers 2024, 16(11), 2157; https://doi.org/10.3390/cancers16112157
Available online: https://www.mdpi.com/2072-6694/16/11/2157

4. “VISTA Emerges as a Promising Target against Immune Evasion Mechanisms in Medulloblastoma”
by Natalia Muñoz Perez, Juliana M. Pensabene, Phillip M. Galbo, Jr., Negar Sadeghipour, Joanne Xiu, Kirsten Moziak, Rita M. Yazejian, Rachel L. Welch, W. Robert Bell, Soma Sengupta et al.
Cancers 2024, 16(15), 2629; https://doi.org/10.3390/cancers16152629
Available online: https://www.mdpi.com/2072-6694/16/15/2629

5. “Acute Pancreatitis in Pediatric Acute Lymphoblastic Leukemia (AcuPA Study): A Nationwide Survey in Poland”
by Anna Morawiak, Małgorzata Salamonowicz-Bodzioch, Aleksandra Królak, Krzysztof Kałwak, Joanna Owoc-Lempach, Jerzy Kowalczyk, Joanna Zawitkowska, Tomasz Szczepański, Ninela Irga-Jaworska, Elżbieta Adamkiewicz-Drożyńska et al.
Cancers 2024, 16(15), 2640; https://doi.org/10.3390/cancers16152640
Available online: https://www.mdpi.com/2072-6694/16/15/2640

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

3 June 2025
MDPI INSIGHTS: The CEO's Letter #23 - MDPI Summits Spain & Italy, Ei Compendex, and Editorial Independence

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Highlights from the MDPI Spain Summit in Barcelona (21-22 May)

In May we hosted the MDPI Spain Summit in Barcelona – our second summit in the city following the inaugural one in November 2023.


Stefan Tochev (CEO, MDPI) at the MDPI Spain Summit in Barcelona, 22 May 2025.

Creating a space for exchange of views

The goal of our summits is to bring together Chief Editors of MDPI journals from across disciplines and institutions. These intimate gatherings provide a platform to present the latest developments at MDPI and to initiate open conversations about our journals, the future of open access, and the evolving landscape of scientific publishing.

Most importantly, these are opportunities for in-person connection, providing a more meaningful space for the exchange of views and for building long-term relationships.

Exploring the future of scientific publishing in Spain

The summit took place on 21–22 May and featured a mix of MDPI presentations (including two guest presentations), roundtable discussions, and Q&A sessions. On the first day, we held a focused session with our Chief Editors to gather feedback and have open discussions on their journal development, the peer-review process, and local accreditation systems.


Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI, presents MDPI’s Editorial Process and Peer Review Quality Metrics at the MDPI Spain Summit in Barcelona, 22 May 2025.

I had the pleasure of opening the Summit with a welcome address and an overview of MDPI’s recent milestones. The agenda then included the following sessions:

  • MDPI and Recent Developments in the Spanish Market – Dr. Marta Colomer (Public Affairs Specialist, MDPI)
  • MDPI Editorial Process and Peer Review Quality Metrics – Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI)
  • Open Access in Spain – Dr. Remedios Melero (Researcher, CSIC – guest speaker)
  • AI in Publishing and MDPI's Actions – Dr. Enric Sayas (Business Analyst, MDPI), Daniele Raimondi (Data Scientist, MDPI), and Dr. Alexandre López-Borrull (Researcher, Universitat Oberta de Catalunya – guest speaker)
  • Publication Ethics – Ana Stankovic (Research Integrity and Publication Ethics, MDPI)
  • Opening and Closing remarks were provided by Rocksy Zhang (Editorial Director, MDPI)

We are extremely grateful for the strong engagement shown by our Editors, who were clearly appreciative of the event and the discussions we had. They felt seen and heard, which is a vital prerequisite for building open channels of communication and cultivating productive long-term collaborations.


MDPI colleagues during MDPI Spain Summit in Barcelona (22 May 2025).

A big thank-you to the entire Barcelona team for organizing such a successful event!

Upcoming MDPI Summit events:

  • Italy Summit – Rome (26–27 May)
  • US Summit – Boston, MA (5–6 June)
  • France Summit – Paris (12–13 June)
  • US Summit – Houston, TX (26–27 June)
  • UK Summit – London (16–17 September)
  • Germany Summit – Berlin (18–19 September)
  • Romania Summit – Bucharest (23–24 October)
    ...with more in between, and more to follow.

Impactful Research

50 MDPI Journals Now Indexed in Ei Compendex

Indexing is a key indicator of a journal’s scientific impact. An indexed journal gives research greater visibility and credibility within the global academic community and is recognized for its quality and relevance. While many of our journals are included in major databases such as Web of Science and Scopus, MDPI also places strong emphasis on journal inclusion in subject-specific indexing platforms that align with each journal’s scope. This ensures that when you publish with MDPI, you publish with impact.

I’m pleased to share that as at May 2025, 51 of our journals are now indexed in Ei Compendex, a leading bibliographic database for engineering and applied sciences. This is a major milestone that reflects both the quality or our editorial processes and the relevance of the research we publish in these fields.

“When you publish with MDPI, you publish with impact”

Discoverability and reach

Inclusion in Ei Compendex means greater discoverability for our authors and broader reach of our journals in the fields of engineering and technology. It improves our ability to support global research and innovation, while building MDPI’s reputation in the applied sciences. This recognition is the result of the dedicated work of our editorial teams, reviewers, and authors, and of our overall commitment to excellence in publishing.

You can read our full announcement here.

Appreciative thanks to everyone involved in reaching this milestone.

Inside MDPI

 

One Year of MDPI’s Seoul Office

On 29 April, we marked one year since the opening of our Seoul office, MDPI’s first local hub in South Korea. South Korea is a key market for MDPI, currently ranking as our sixth-largest contributor to the company’s total publications, with over 89,000 MDPI articles authored by individuals affiliated with Korean institutions. Over the past 12 months, the Seoul team has made great strides in building our visibility, networks, and presence in the region.

A few highlights from the past year


Claude Seo (MDPI Korea Office Manager, Seoul)

Claude Seo, who has over 15 years of experience in the academic publishing industry, is the Office Manager of the Seoul office.

In its inaugural year, the Seoul office focused primarily on marketing and promotional activities to support the MDPI brand locally. During that time, the team concentrated on scholar visits to local institutions, attending academic conferences, and hosting editorial board meetings.

The team also secured 10 Institutional Open Access Program (IOAP) renewals, signed three new IOAP agreements, and established one new Society affiliation.

The Seoul office also hosted its first library book fair and reached over 1,000 followers on its LinkedIn channel, which is an encouraging indication of local visibility and engagement.

“The Seoul team has made strides in building our visibility, networks, and presence in the region”

Growth plans

Later this year, we are working on opening a new Seoul office in a more central location, with room for our growing team. The new space will bring us closer to other publishing partners and provide easier access to and from the airport. The Seoul office will continue to expand its efforts in outreach and engagement as its builds its presence in South Korea.

Warm thanks to the entire Seoul team for their hard work and dedication, and to all MDPI colleagues who have contributed to this exciting chapter in our global journey.

Coming Together for Science

Highlights from the MDPI Italy Summit in Rome (26–27 May)

We closed the month of May by hosting the first MDPI Italy Summit in Rome. This was an important event for us, as Italy has consistently ranked among the top ten countries globally for open access publications over the past decade.

MDPI and Italy: Facts & Figures

  • With over 144,000 publications (as at 31 May 2025), Italy is MDPI’s third largest contributor after China and the USA.
  • In 2024, MDPI was the second-largest publishing house in Italy.
  • The 7,165 Editorial Board Members (EBMs) drawn from Italian institutions represent 8.9% of all MDPI academic editors.
  • Among these, 319 serve as Editors-in-Chief (EiCs) or Section Editors-in-Chief (SEiCs).
  • Eleven Italian EBMs were recognized as 2024 Clarivate Highly Cited Researchers.
  • In 2024, MDPI received 24,873 review reports and collaborated with 88,578 reviewers from Italy.
  • 23,131 Guest Editors from Italian institutions led 4,827 Special Issues across 248 MDPI journals.
  • MDPI partners with over 900 institutions globally, of which 17 are in Italy.

The MDPI Italy Summit in Rome


Dr. Prof. Giulio Cerullo, EiC of Applied Sciences, at the MDPI Italy Summit in Rome (27 May 2025).

Held on 26–27 May, the MDPI Italy Summit brought together 25 Chief Editors from across our journal portfolio, including some of our largest journals such as Applied Sciences, to discuss MDPI’s latest developments and collaborations in the Italian market, our use of data intelligence and AI to support strategic decision-making, a look into our editorial process, peer-review quality metrics, and conversations around research integrity and community engagement.

The Summit featured MDPI presentations followed by Q&A and concluded with a roundtable discussion. On the evening of the 26th, we hosted a dinner with our Editors to connect personally, learn more about their research, and hear feedback on journal operations and the broader academic landscape in Italy.


Gathering of Editors-in-Chief and MDPI staff at the MDPI Italy Summit in Rome (27 May 2025).

Event Agenda – 27 May

Moderated by Maddalena Favaretto (Conference Scientific Advisor, MDPI), the program featured:

  • MDPI Overview, Achievements, Latest News and Future Developments – Stefan Tochev (CEO, MDPI)
  • Country Report: Italy – Dr. Laura Perez Martin (Conference Assistant, MDPI)
  • AI in Publishing and MDPI’s Actions – Dr. Andrea Perlato (Head of Data Analytics, MDPI)
  • MDPI Editorial Process and Research Integrity – Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI)
  • Panel Discussion – Stefan, Andrea, Giulia


Panel Discussion with Stefan Tochev (CEO, MDPI), Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI), Dr. Andrea Perlato (Head of Data Analytics, MDPI) during the MDPI Italy Summit in Rome (27 May 2025).

A big thank-you to our Conference team and everyone who worked behind the scenes to make these events run smoothly.

Closing Thoughts

Upholding Editorial Independence in Scholarly Publishing

A recent MDPI blog post written by Dr. Ioana Craciun (Scientific Communications Specialist, MDPI), “Editorial Independence and Publisher Support: Collaborating to Uphold Integrity,” highlights the important balance between editorial autonomy and publisher collaboration in academic publishing.

As the leading fully Open Access scholarly publisher, we are proud to champion editorial independence within our publishing process.

Drawing from the Committee on Publication Ethics (COPE) guidelines, the article emphasizes that while editors must have the freedom to make decisions based on scholarly merit, publishers play a critical role in providing the necessary infrastructure and tools to support the editorial process. This collaborative approach ensures the integrity of the peer review process, builds trust among authors and readers, and upholds the quality and relevance of published content.

MDPI highlights its commitment to this model by investing in research integrity specialists, AI tools for plagiarism detection, and administrative support, all aimed at empowering editors to make independent, informed decisions.

Stefan Tochev
Chief Executive Officer
MDPI AG

Back to TopTop